Progress in corticotropin-releasing factor-1 antagonist development
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Corticotropin-releasing factor (CRF) receptor antagonists have been sought since the stress-secreted peptide was isolated in 1981. Although evidence suggests the limited efficacy of CRF1 antagonists as antidepressants, CRF1 antagonists might be novel pharmacotherapies for anxiety and addiction. Progress in understanding the two-domain model of ligand–receptor interactions for CRF family receptors might yield chemically novel CRF1 receptor antagonists, including peptide CRF1 antagonists, antagonists with signal transduction selectivity and nonpeptide CRF1 antagonists that act via the extracellular (rather than transmembrane) domains. Novel ligands that conform to prevalent pharmacophore and exhibit drug-like pharmacokinetic properties have been identified. The therapeutic utility of CRF1 antagonists should soon be clearer: several small molecules are currently in Phase II/III clinical trials for depression, anxiety and irritable bowel syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056 · cited 1×
“Consistent with this hypothesis, both the HPA axis and extrahypothalamic CRF systems are activated during acute withdrawal from all major drugs of abuse in animal models [60], and central infusion of non-peptide CRF antagonists block the anxiogenic-like responses observed during acute withdrawal from drugs of abuse, i…”
Self-citationStress dysregulation of drug reward pathways, and the transition to drug dependence
Koob, & Kreek, M. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05030503 · Cited by 868 · cited 1×
“Consistent with this hypothesis, both the HPA axis and extrahypothalamic CRF systems are activated during acute withdrawal from all major drugs of abuse in animal models [60], and central infusion of non-peptide CRF antagonists block the anxiogenic-like responses observed during acute withdrawal from drugs of abuse, i…”
Corticotropin-Releasing Factor in Brain: A Role in Activation, Arousal, and Affect Regulation
Heinrichs, S. C., & Koob, G. F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052092 · Cited by 353 · cited 1×
“Pharmacological and transgenic studies show that brain and pituitary CRF1 receptors mediate endocrine, behavioral and autonomic responses to stress [4].”
BackgroundSelf-citationSommer, W. H., Rimondini, R., Hansson, A. C., Hipskind, P. A., Gehlert, D. R., Barr, C. S., & Heilig, M. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.010 · Cited by 309 · cited 1×
“Similarly, systemic administration of blood–brain-barrier-penetrating CRF1 antagonists reduced the anxiogenic-, aversive- and hypohedonic-like effects of withdrawal from opioids [62–65], nicotine [56,66], benzodiazepines [63] and alcohol [29,54, 55,67,68].”
BackgroundShaham, Y., Erb, S., Leung, S., Buczek, Y., & Stewart, J. (1998) · Psychopharmacology · doi:10.1007/s002130050608 · Cited by 302
Funk, C. K., Zorrilla, E. P., Lee, M.-J., Rice, K. C., & Koob, G. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.063 · Cited by 276
Self-citationBinneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · cited 1×
“By contrast, development of ONO-2333Ms and CP-316311 were discontinued because of negative efficacy results in double-blind, placebo-controlled trials for major depression [99].”
ResultGeorge, O., Ghozland, S., Azar, M. R., Cottone, P., Zorrilla, E. P., Parsons, L. H., O'Dell, L. E., Richardson, H. N., & Koob, G. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707585104 · Cited by 245 · cited 2×
“Supporting the motivational significance of withdrawal-associated CRF1 system activation for drug taking, administration of small-molecule CRF1 antagonists also reduced the excessive drug intake associated with dependence on alcohol [50–55,69], nicotine [56], cocaine [57] and opioids [58].”
BackgroundSelf-citation
Cited by
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Role of Corticotropin-Releasing Factor in Drug Addiction: Potential for Pharmacological Intervention
Logrip, M. L., Koob, G. F., & Zorrilla, E. P. (2011) · CNS Drugs · doi:10.2165/11587790-000000000-00000 · Cited by 476
Self-citationAddiction and Brain Reward and Antireward Pathways
Gardner, E. L. (2011) · Advances in Psychosomatic Medicine · doi:10.1159/000324065 · Cited by 417
Structure of class B GPCR corticotropin-releasing factor receptor 1
Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K. Y., Doré, A. S., Jazayeri, A., Cooke, R. M., Weir, M., & Marshall, F. H. (2013) · Nature · doi:10.1038/nature12357 · Cited by 416
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity
Gerhard, D. M., Wohleb, E. S., & Duman, R. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.016 · Cited by 261
Hormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer, J. B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C. I., Carpenter, L. L., Nemeroff, C. B., McDonald, W. M., Kalin, N. H., & APA Council of Research Task Force on Novel Biomarkers and Treatments (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080848 · Cited by 252
“controlled trials yielded negative results or were stopped early because of lack of efficacy (ONO-2333Ms [N=278] [50], CP-316,311 [N=123] [53], BMS-562086 [N=260 forgeneralized anxiety disorder (54); trial ended unpublished for major”
Role of kappa-opioid receptors in stress and anxiety-related behavior
Van’t Veer, A., & Carlezon, W. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3195-5 · Cited by 257
Corticotropin releasing factor: A key role in the neurobiology of addiction
Zorrilla, E. P., Logrip, M. L., & Koob, G. F. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.001 · Cited by 254
Self-citationSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Self-citationBrain and gut CRF signaling: biological actions and role in the gastrointestinal tract
Tache, Y., Larauche, M., Yuan, P.-Q., & Million, M. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467210666170224095741 · Cited by 147
“Rivier [16], selective non peptide CRFR1 antagonists [17] (Table 1), and genetically modified mice [18].”
BackgroundInfluentialThe neurobiological correlates of childhood adversity and implications for treatment
Tyrka, A. R., Burgers, D. E., Philip, N. S., Price, L. H., & Carpenter, L. L. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12143 · Cited by 142
“Clinical trials for depression have not been successful or have found problems with safety or efficacy (88), but studies of other disorders, including PTSD, are ongoing.”
BackgroundDepressive disorders: treatment failures and poor prognosis over the last 50 years
Blackburn, T. P. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.472 · Cited by 136
The Role of the Central Amygdala in Alcohol Dependence
Roberto, M., Kirson, D., & Khom, S. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039339 · Cited by 112
Ding, Y., Wei, Z., Yan, H., & Guo, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732157 · Cited by 34
“Some medications had initial promising results but were then discontinued (Serradeil-Le Gal et al., 2005; Sanofi-Aventis, 2008), and several compounds had been abandoned due to their severe side effects or lack of efficacy (Binneman et al., 2008; Zorrilla and Koob, 2010; Dwyer et al., 2020).”
BackgroundLangenecker, S. A., Crane, N. A., Jenkins, L. M., Phan, K. L., & Klumpp, H. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0140-2 · Cited by 11
Metadata
- Authors
- Zorrilla, E. P., & Koob, G. F.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 15
- Issue
- 9-10
- Pages
- 371-383
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1968329392
- Cited by
- 167
- References
- 18
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.